melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Seven people were killed in a Russian attack on the offices of Ukraine's largest printing house, located in Kharkiv. One person was killed in a separate attack in Zaporizhzhia Oblast. Russian-installed authorities in Crimea claimed that two people were killed in a Ukrainian missile attack in Simferopol Raion. The pro-Ukrainian partisan group Atesh claimed that the attack targeted a communications hub in Alushta, while other attacks were reported on a military antenna in Semydviria, Belbek airfield and in Yevpatoria. Ukraine claimed to have shot down a Russian Su-25 jet over the Donbas. Several sources questioned this claim, stating that the footage of the incident appeared to have been taken from a video game. Russia claimed to have shot down a drone over Tatarstan. Officials claimed that one person was killed in a drone strike in Belgorod Oblast. Norway pledged a $190 million military aid package to Ukraine that included support for air defense, naval capabilities, radar, anti-drone systems, and boats. Russia warned the UK that it could strike British targets "on Ukraine's territory and beyond its borders" if weapons it supplied to Ukraine are used against targets on Russian soil. The first group of Ukrainian pilots passed the US F-16 training program at Morris Air National Guard Base in Arizona and will undergo further training in Europe. Putin signed a decree allowing the assets of the United States, its citizens, and its companies to be confiscated and used for compensation for losses incurred by international sanctions.
A medical laboratory or clinical laboratory is a laboratory where tests are conducted out on clinical specimens (e.g. Blood, urine, stool, sputum and other body tissues) to obtain information about the health of a patient to aid in diagnosis, treatment, and prevention of disease. Clinical medical laboratories are an example of applied science, as opposed to research laboratories that focus on basic science, such as found in some academic institutions. Medical laboratories vary in size and complexity and so offer a variety of testing services. More comprehensive services can be found in acute-care hospitals and medical centers, where 70% of clinical decisions are based on laboratory testing. Doctors offices and clinics, as well as skilled nursing and long-term care facilities, may have laboratories that provide more basic testing services. Commercial medical laboratories operate as independent businesses and provide testing that is otherwise not provided in other settings due to low test volume or complexity.
== Pharmacology == Butorphanol exhibits partial agonist and antagonist activity at the μ-opioid receptor, as well as partial agonist activity at the κ-opioid receptor (Ki = 2.5 nM; EC50 = 57 nM; Emax = 57%). Stimulation of these receptors on central nervous system neurons causes an intracellular inhibition of adenylate cyclase, closing of influx membrane calcium channels, and opening of membrane potassium channels. This leads to hyperpolarization of the cell membrane potential and suppression of action potential transmission of ascending pain pathways. Because of its κ-agonist activity, at analgesic doses butorphanol increases pulmonary arterial pressure and cardiac work. Additionally, κ-agonism can cause dysphoria at therapeutic or supratherapeutic doses; this gives butorphanol a lower potential for abuse than other opioid drugs.
=== Legal status === In February 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hyftor, intended for the treatment of angiofibroma. The applicant for this medicinal product is Plusultra pharma GmbH. Hyftor was authorized for medical use in the European Union in May 2023. Sirolimus, as Rapamune solution, was approved for medical use in the United States in 1999; and as Rapamune tablets in August 2000. Sirolimus, as Fyarro, was approved for medical use in the United States in November 2021. Sirolimus, as Hyftor, was approved for medical use in the United States in March 2022.
After at least three months, other effects are expected, such as the deepening of the voice and changes in sexual organs (such as atrophy of vaginal tissues, and increased clitoral size). Regular monitoring by an endocrinologist is a strong recommendation to ensure the safety of individuals as they transition. Access to hormone replacement therapy has been shown to improve quality of life for people in the female-to-male community when compared to female-to-male people who do not have access to hormone replacement therapy. Feminizing therapy has also been found to improve well-being. Interestingly, one systematic review determined that "Overall, the qualitative literature tended to support positive changes in well-being among people after starting feminizing hormone therapy, although often with the qualification that improvements in well-being were attributed to satisfaction with changes in appearance rather than to direct effects of hormones on psychosocial states." Hormone therapy for transgender individuals has been shown in medical literature to be safe, when supervised by a qualified medical professional. Monitoring of risk factors associated with hormone replacement therapy, such as prolactin levels in transgender women and polycythemia levels in transgender men, are crucial for the preventive health care of transgender people taking these treatments. Many transgender people lack access to a supportive, high quality, non-discriminatory health care system.
Sources: en.wikipedia.org
=== Alternatives === There is strong evidence that chlorhexidine and alcohol used to clean skin prior to surgery is better than any formulation of povidone-iodine. While the 2016 World Health Organization guidelines recommended alcohol-based CHG Chlorhexidine for surgical skin preparation based on low-to-moderate quality evidence, subsequent clinical data has clarified this comparison. A large-scale 2024 non-inferiority trial involving over 3,300 patients undergoing cardiac or abdominal surgeries found that alcohol-based povidone-iodine is non-inferior to alcohol-based CHG Chlorhexidine in preventing surgical site infections (SSIs).
The identity of Jack the Ripper is a notorious example of an outstanding cold case, with numerous suggestions as to the identity of the serial killer. Similarly, the Zodiac Killer has been studied extensively for almost 50 years, with numerous suspects discussed and debated. The perpetrators of the Wall Street bombing of 1920 have never been positively identified, though the Galleanists, a group of Italian anarchists, are widely believed to have planned the explosion. The burning of the Reichstag building in 1933 remains controversial and although Marinus van der Lubbe was tried, convicted and executed for arson, it is possible that the Reichstag fire was perpetrated by the Nazis to enhance their power and destroy democracy in Germany.
=== Acidity === The methyl groups of DMSO are only weakly acidic, with a pKa = 35. For this reason, the basicities of many weakly basic organic compounds have been examined in this solvent. Deprotonation of DMSO requires strong bases like lithium diisopropylamide and sodium hydride. Stabilization of the resultant carbanion is provided by the S(O)R group. The sodium derivative of DMSO formed in this way is referred to as dimsyl sodium. It is a base, e.g., for the deprotonation of ketones to form sodium enolates, phosphonium salts to form Wittig reagents, and formamidinium salts to form diaminocarbenes. The dimsyl anion is a potent nucleophile.
MS1 is a positive allosteric modulator (PAM) of the μ-opioid receptor (MOR). It was developed from structural modification of the earlier MOR PAM BMS‐986122. The drug has been found to augment the affinity of the MOR agonist levomethadone ((R)-methadone) for the MOR by 7-fold in vitro and to potentiate activation of the MOR by levomethadone by 4-fold in a G protein assay. However, MS1 displays strong probe dependence, and while it potentiates the MOR agonists levomethadone and morphine, it had no effect on the affinity or potency of the MOR agonists DAMGO or endomorphin-1. MS1 shows a preference for β-arrestin recruitment over G protein activation with endomorphin-1 exposure. The drug's actions are reportedly similar to those of BMS-986122, though its unclear if their mechanisms of action are the same. MS1 shows potentiated analgesic effects with opioids in animals. It also did not worsen opioid withdrawal symptoms, respiratory depression, or analgesic tolerance. MS1 and other atypical MOR activators are of potential interest in the development of novel opioid analgesics with reduced adverse effects and misuse potential. MS1 has notably been found to penetrate the blood–brain barrier in animals. The potential of the related MOR PAMs BMS-986121 and BMS-986122 as pharmaceutical drugs has been restricted owing to their complex chemical synthesis. MS1 has a much simpler synthesis in comparison and hence has been regarded as having overcome this limitation. MS1 was first described in the scientific literature by 2015.
Sources: en.wikipedia.org
=== Gutter oil in other countries === Gutter oil has also been used outside of China as well, albeit not for human consumption. For example, in England, fatbergs that were dug out of sewers in cities like London and Liverpool were later reported to be processed to produce biofuel.
Additionally, defects in both GSY1 and the SCNA4 gene, responsible for hyperkalemic periodic paralysis (HYPP) in Quarter Horses and related breeds, has been found in 14% of Halter horses. A combination of both of these genes can cause severe rhabdomyolysis should the horse become recumbent due to an HYPP attack.
==== 2200–2299 ==== Motor Vehicles (Type Approval for Goods Vehicles) (Great Britain) (Amendment) Regulations 1993 (S.I. 1993/2200) Motor Vehicles (Type Approval) (Great Britain) (Amendment) Regulations 1993 (S.I. 1993/2201) Bananas (Interim Measures) (Revocation) Regulations 1993 (S.I. 1993/2204) Wireless Telegraphy (Television Licence Fees) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2205) National Health Service (General Dental Services) Amendment Regulations 1993 (S.I. 1993/2209) Dental Vocational Training Authority Regulations 1993 (S.I. 1993/2210) Dental Vocational Training Authority (Establishment and Constitution) and Appeal Body (Specification) Order 1993 (S.I. 1993/2211) Taxes (Interest Rate) (Amendment No. 3) Regulations 1993 (S.I. 1993/2212) Friendly Societies Act 1992 (Commencement No. 6 and Transitional Provisions) Order 1993 (S.I. 1993/2213) Finance Act 1993 (Appointed Day) Order 1993 (S.I. 1993/2214) Finance Act 1993, section 12, (Appointed Day) Order 1993 (S.I. 1993/2215) National Health Service (District Health Authorities) (No.2) Order 1993 (S.I. 1993/2218) National Health Service (Determination of Districts) (No.2) Order 1993 (S.I. 1993/2219) National Health Service (General Dental Services) (Scotland) Amendment Regulations 1993 (S.I. 1993/2224) Parole Board (Scotland) Rules 1993 (S.I. 1993/2225) Transcripts of Criminal Proceedings (Scotland) Order 1993 (S.I. 1993/2226) Prison (Scotland) Amendment Rules 1993 (S.I. 1993/2227) Young Offenders (Scotland) Amendment Rules 1993 (S.I. 1993/2228) Road Traffic Act 1991 (Commencement No.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.